A study to investigate the safety and efficacy of MEDI0618 compared to placebo in adult participants with episodic migraine - AURORA

Study identifier:D7060C00003

ClinicalTrials.gov identifier:NCT06602479

EudraCT identifier:N/A

CTIS identifier:2024-512904-21-00

Recruiting

Official Title

A Phase 2, Randomised, Multicentre, Parallel-Group Treatment, Double-Blind Study to Investigate the Safety and Efficacy of Subcutaneous MEDI0618 in the Reduction of Migraine Headache Days Compared to Placebo in Adult Participants with Episodic Migraine

Medical condition

migraine

Phase

Phase 2

Healthy volunteers

No

Study drug

MEDI0618, Placebo

Sex

All

Estimated Enrollment

408

Study type

Interventional

Age

18 Years - 70 Years

Date

Study Start Date: 07 Oct 2024
Estimated Primary Completion Date: 07 Sept 2026
Estimated Study Completion Date: 07 Sept 2026

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Prevention

Verification:

Verified 01 Oct 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria